Sunflower Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
August 09, 2022 at 03:54 am EDT
Share
Sunflower Pharmaceutical Group Co.,Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 2,241.31 million compared to CNY 2,096.94 million a year ago. Revenue was CNY 2,249.17 million compared to CNY 2,101.74 million a year ago. Net income was CNY 401.22 million compared to CNY 307.3 million a year ago. Basic earnings per share from continuing operations was CNY 0.7 compared to CNY 0.53 a year ago. Diluted earnings per share from continuing operations was CNY 0.7 compared to CNY 0.53 a year ago.
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.